213 related articles for article (PubMed ID: 33844099)
1. SETD2 alterations and histone H3K36 trimethylation in phyllodes tumor of breast.
Tsang JY; Lai ST; Ni YB; Shao Y; Poon IK; Kwan JS; Chow C; Shea KH; Tse GM
Breast Cancer Res Treat; 2021 Jun; 187(2):339-347. PubMed ID: 33844099
[TBL] [Abstract][Full Text] [Related]
2. The Benzene Hematotoxic and Reactive Metabolite 1,4-Benzoquinone Impairs the Activity of the Histone Methyltransferase SET Domain Containing 2 (SETD2) and Causes Aberrant Histone H3 Lysine 36 Trimethylation (H3K36me3).
Berthelet J; Michail C; Bui LC; Le Coadou L; Sirri V; Wang L; Dulphy N; Dupret JM; Chomienne C; Guidez F; Rodrigues-Lima F
Mol Pharmacol; 2021 Sep; 100(3):283-294. PubMed ID: 34266924
[TBL] [Abstract][Full Text] [Related]
3. SETD2-dependent H3K36me3 plays a critical role in epigenetic regulation of the HPV31 life cycle.
Gautam D; Johnson BA; Mac M; Moody CA
PLoS Pathog; 2018 Oct; 14(10):e1007367. PubMed ID: 30312361
[TBL] [Abstract][Full Text] [Related]
4. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas.
Fontebasso AM; Schwartzentruber J; Khuong-Quang DA; Liu XY; Sturm D; Korshunov A; Jones DT; Witt H; Kool M; Albrecht S; Fleming A; Hadjadj D; Busche S; Lepage P; Montpetit A; Staffa A; Gerges N; Zakrzewska M; Zakrzewski K; Liberski PP; Hauser P; Garami M; Klekner A; Bognar L; Zadeh G; Faury D; Pfister SM; Jabado N; Majewski J
Acta Neuropathol; 2013 May; 125(5):659-69. PubMed ID: 23417712
[TBL] [Abstract][Full Text] [Related]
5. Structure/Function Analysis of Recurrent Mutations in SETD2 Protein Reveals a Critical and Conserved Role for a SET Domain Residue in Maintaining Protein Stability and Histone H3 Lys-36 Trimethylation.
Hacker KE; Fahey CC; Shinsky SA; Chiang YJ; DiFiore JV; Jha DK; Vo AH; Shavit JA; Davis IJ; Strahl BD; Rathmell WK
J Biol Chem; 2016 Sep; 291(40):21283-21295. PubMed ID: 27528607
[TBL] [Abstract][Full Text] [Related]
6. The SETD2 Methyltransferase Supports Productive HPV31 Replication through the LEDGF/CtIP/Rad51 Pathway.
Mac M; DeVico BM; Raspanti SM; Moody CA
J Virol; 2023 May; 97(5):e0020123. PubMed ID: 37154769
[TBL] [Abstract][Full Text] [Related]
7. SETD2: an epigenetic modifier with tumor suppressor functionality.
Li J; Duns G; Westers H; Sijmons R; van den Berg A; Kok K
Oncotarget; 2016 Aug; 7(31):50719-50734. PubMed ID: 27191891
[TBL] [Abstract][Full Text] [Related]
8. High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma.
Ho TH; Park IY; Zhao H; Tong P; Champion MD; Yan H; Monzon FA; Hoang A; Tamboli P; Parker AS; Joseph RW; Qiao W; Dykema K; Tannir NM; Castle EP; Nunez-Nateras R; Teh BT; Wang J; Walker CL; Hung MC; Jonasch E
Oncogene; 2016 Mar; 35(12):1565-74. PubMed ID: 26073078
[TBL] [Abstract][Full Text] [Related]
9. Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma.
Liu W; Fu Q; An H; Chang Y; Zhang W; Zhu Y; Xu L; Xu J
Medicine (Baltimore); 2015 Nov; 94(45):e2004. PubMed ID: 26559293
[TBL] [Abstract][Full Text] [Related]
10. SPOP-containing complex regulates SETD2 stability and H3K36me3-coupled alternative splicing.
Zhu K; Lei PJ; Ju LG; Wang X; Huang K; Yang B; Shao C; Zhu Y; Wei G; Fu XD; Li L; Wu M
Nucleic Acids Res; 2017 Jan; 45(1):92-105. PubMed ID: 27614073
[TBL] [Abstract][Full Text] [Related]
11. Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patients.
Liu L; Guo R; Zhang X; Liang Y; Kong F; Wang J; Xu Z
Biosci Trends; 2017 May; 11(2):214-220. PubMed ID: 28260718
[TBL] [Abstract][Full Text] [Related]
12. SETD2 histone modifier loss in aggressive GI stromal tumours.
Huang KK; McPherson JR; Tay ST; Das K; Tan IB; Ng CC; Chia NY; Zhang SL; Myint SS; Hu L; Rajasegaran V; Huang D; Loh JL; Gan A; Sairi AN; Sam XX; Dominguez LT; Lee M; Soo KC; Ooi LL; Ong HS; Chung A; Chow PK; Wong WK; Selvarajan S; Ong CK; Lim KH; Nandi T; Rozen S; Teh BT; Quek R; Tan P
Gut; 2016 Dec; 65(12):1960-1972. PubMed ID: 26338826
[TBL] [Abstract][Full Text] [Related]
13. SETD2, an epigenetic tumor suppressor: a focused review on GI tumor.
Hu M; Hu M; Zhang Q; Lai J; Liu X
Front Biosci (Landmark Ed); 2020 Jan; 25(4):781-797. PubMed ID: 31585917
[TBL] [Abstract][Full Text] [Related]
14. SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia.
Bu J; Chen A; Yan X; He F; Dong Y; Zhou Y; He J; Zhan D; Lin P; Hayashi Y; Sun Y; Zhang Y; Xiao Z; Grimes HL; Wang QF; Huang G
Leukemia; 2018 Apr; 32(4):890-899. PubMed ID: 29249820
[TBL] [Abstract][Full Text] [Related]
15. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes.
Xie Y; Sahin M; Sinha S; Wang Y; Nargund AM; Lyu Y; Han S; Dong Y; Hsieh JJ; Leslie CS; Cheng EH
Nat Cancer; 2022 Feb; 3(2):188-202. PubMed ID: 35115713
[TBL] [Abstract][Full Text] [Related]
16. Identification of functional cooperative mutations of SETD2 in human acute leukemia.
Zhu X; He F; Zeng H; Ling S; Chen A; Wang Y; Yan X; Wei W; Pang Y; Cheng H; Hua C; Zhang Y; Yang X; Lu X; Cao L; Hao L; Dong L; Zou W; Wu J; Li X; Zheng S; Yan J; Zhou J; Zhang L; Mi S; Wang X; Zhang L; Zou Y; Chen Y; Geng Z; Wang J; Zhou J; Liu X; Wang J; Yuan W; Huang G; Cheng T; Wang QF
Nat Genet; 2014 Mar; 46(3):287-93. PubMed ID: 24509477
[TBL] [Abstract][Full Text] [Related]
17. SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability.
Pfister SX; Ahrabi S; Zalmas LP; Sarkar S; Aymard F; Bachrati CZ; Helleday T; Legube G; La Thangue NB; Porter AC; Humphrey TC
Cell Rep; 2014 Jun; 7(6):2006-18. PubMed ID: 24931610
[TBL] [Abstract][Full Text] [Related]
18. H3K36 trimethylation mediated by SETD2 regulates the fate of bone marrow mesenchymal stem cells.
Wang L; Niu N; Li L; Shao R; Ouyang H; Zou W
PLoS Biol; 2018 Nov; 16(11):e2006522. PubMed ID: 30422989
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells.
Sheng Y; Ji Z; Zhao H; Wang J; Cheng C; Xu W; Wang X; He Y; Liu K; Li L; Voeltzel T; Maguer-Satta V; Gao WQ; Zhu HH
Cell Prolif; 2019 Jul; 52(4):e12611. PubMed ID: 31054182
[TBL] [Abstract][Full Text] [Related]
20. SETD2 as a regulator of N6-methyladenosine RNA methylation and modifiers in cancer.
Kumari S; Muthusamy S
Eur J Cancer Prev; 2020 Nov; 29(6):556-564. PubMed ID: 33021769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]